News from the life sciences community north of Boston
|
|
|
|
|
Cummings Properties is pleased to welcome FuseBio Therapeutics, a biotechnology company that is dedicated to developing transformative immune modulating therapies for patients with cancer, to 7 Henshaw Street in Woburn. FuseBio's platform transforms antibodies to enhance immune response to eradicate tumors without killing healthy tissue. Brian Rabinovich is co-founder and chief scientific officer.
|
|
Hopewell Therapeutics will move from Boston to an incubator-size lab at 310 West Cummings Park in Woburn. The company is developing novel synthetic biodegradable lipid-based nanoparticles for nucleic acid delivery for gene therapy and gene editing. The technology is licensed from Tufts University. Qi Jang, Ph.D. is the company's general manager.
|
|
|
|
|
"I looked at this as a perfect opportunity to create a patient-centric company around fragile patients that otherwise are not well-served by the pharmaceutical biologics that are available, that have been approved by the FDA. It's a mission of love to try and see if we can make the world a better place and make very nice financial returns to the investors in doing so."
Jim Sherblom
Chairman of the Board, ReForm Biologics
|
|
MassBioDrive Launch, presented by MassBio. Celebrate the launch of this next-generation biotech accelerator, and network with other professionals. Wednesday, January 19, at 5:30 PM (virtual). Register.
|
|
Growth for North Shore Innoventures
|
|
The latest expansion of North Shore InnoVentures (NSIV) at Cummings Center is complete! This 5,000 SF construction project with 600 SF of dedicated condo space is now ready for new life sciences and cleantech startups.
|
|
NSIV also recently welcomed new member Shepherd Therapeutics. Founder David Hysong was diagnosed with Adenoid Cystic Carcinoma (ACC) - an ultra-rare, untreatable head and neck cancer at age 27. This form of cancer, like many others, does not respond to chemotherapy and has no approved targeted therapies. Refusing to accept this, David founded Shepherd for the millions of Americans battling rare cancer.
|
|
Endolytix Technology Inc., founded by chief science officer Jason Holder, Ph.D., recently occupied its brand-new office and lab space at 48 Dunham Ridge. Endolytix is a life sciences company that is developing a new therapeutic approach to address antibiotic resistance. With room to grow, Endolytix is hiring - check out the company's Careers page for open positions.
|
|
3,000 SF Lab Available in Woburn - Spring 2022
|
|
|
This recently completed lab space is ideally located in Woburn's vibrant life sciences cluster, close to both I-95 and I-93, with numerous amenities nearby, including dining, shopping, and services. Suite features include:
|
|
- 6' fume hood
- Process piping
- Three separate lab areas
- Access to shared loading
- Ample bench top and cabinets
|
|
Subscribe to our newsletter!
Make new professional connections and gain visibility for your life sciences enterprise via this newsletter. If you have news to share, contact Sue Howland at svh@cummings.com. Please forward this edition to additional members of your team or others in your network who would benefit from its informative content, or send us email addresses for colleagues who would like to receive future updates.
|
|
Our partners at Massachusetts Life Sciences Center (MLSC) will soon launch the next round of its Tax Incentive program supporting companies engaged in life sciences research and development, commercialization, and manufacturing in Massachusetts. The program provides incentives to companies of all sizes looking to expand their efforts by creating new, long-term jobs in Massachusetts.
Cummings Properties is proud to host MLSC’s informational session for companies wanting to learn more about the eligibility requirements of the Tax Incentive program. Join us at 300 TradeCenter (Suite 7610) in Woburn on Thursday, December 16 at 11:00 AM. Advance registration is required.
|
|
Save the Date! North Shore Technology Council will host a Fireside Chat with Joe Boncore, CEO, and Kendalle Burlin O'Connell, president and chief operating officer, of MassBio Thursday, January 20 at noon. Stay tuned for registration details in our next newsletter.
|
|
Have news to share? Please let us know! We are interested in company news, personnel changes, product launches, funding updates, events, and more. Contact Sue Howland, client engagement manager, at svh@cummings.com to share your news for upcoming newsletters. We look forward to hearing from you.
|
|
|
|
|
|
|
